549 related articles for article (PubMed ID: 33924419)
1. Phosphate, Microbiota and CKD.
Favero C; Carriazo S; Cuarental L; Fernandez-Prado R; Gomá-Garcés E; Perez-Gomez MV; Ortiz A; Fernandez-Fernandez B; Sanchez-Niño MD
Nutrients; 2021 Apr; 13(4):. PubMed ID: 33924419
[TBL] [Abstract][Full Text] [Related]
2. Derangements in phosphate metabolism in chronic kidney diseases/endstage renal disease: therapeutic considerations.
Molony DA; Stephens BW
Adv Chronic Kidney Dis; 2011 Mar; 18(2):120-31. PubMed ID: 21406297
[TBL] [Abstract][Full Text] [Related]
3. Prevention and control of phosphate retention/hyperphosphatemia in CKD-MBD: what is normal, when to start, and how to treat?
Martin KJ; González EA
Clin J Am Soc Nephrol; 2011 Feb; 6(2):440-6. PubMed ID: 21292848
[TBL] [Abstract][Full Text] [Related]
4. Management of phosphorus load in CKD patients.
Taketani Y; Koiwa F; Yokoyama K
Clin Exp Nephrol; 2017 Mar; 21(Suppl 1):27-36. PubMed ID: 27896453
[TBL] [Abstract][Full Text] [Related]
5. Gut microbiota; an overlooked effect of phosphate binders.
Rahbar Saadat Y; Niknafs B; Hosseiniyan Khatibi SM; Ardalan M; Majdi H; Bahmanpoor Z; Abediazar S; Zununi Vahed S
Eur J Pharmacol; 2020 Feb; 868():172892. PubMed ID: 31870830
[TBL] [Abstract][Full Text] [Related]
6. Contribution of Gut Microbiota-Derived Uremic Toxins to the Cardiovascular System Mineralization.
Filipska I; Winiarska A; Knysak M; Stompór T
Toxins (Basel); 2021 Apr; 13(4):. PubMed ID: 33920096
[TBL] [Abstract][Full Text] [Related]
7. Management of CKD-MBD in non-dialysis patients under regular nephrology care: a prospective multicenter study.
Gallieni M; De Luca N; Santoro D; Meneghel G; Formica M; Grandaliano G; Pizzarelli F; Cossu M; Segoloni G; Quintaliani G; Di Giulio S; Pisani A; Malaguti M; Marseglia C; Oldrizzi L; Pacilio M; Conte G; Dal Canton A; Minutolo R
J Nephrol; 2016 Feb; 29(1):71-8. PubMed ID: 25986389
[TBL] [Abstract][Full Text] [Related]
8. The role of phosphate-containing medications and low dietary phosphorus-protein ratio in reducing intestinal phosphorus load in patients with chronic kidney disease.
Li J; Wang L; Han M; Xiong Y; Liao R; Li Y; Sun S; Maharjan A; Su B
Nutr Diabetes; 2019 Apr; 9(1):14. PubMed ID: 30944300
[TBL] [Abstract][Full Text] [Related]
9. [Management of bone and mineral metabolism disorders before the dialysis stage remains still perfectible. Data from the French Phosphorus and Calcium Survey Photo-Graphe].
Jean G; Daugas É; Roth H; Drueke T; Bouchet JL; Hannedouche T; London G; Fouque D
Nephrol Ther; 2017 Nov; 13(6):470-478. PubMed ID: 28843391
[TBL] [Abstract][Full Text] [Related]
10. Phosphate binders in moderate chronic kidney disease: where do we stand?
Bellasi A; Cozzolino M; Adragao T; Di Iorio B; Russo D
J Nephrol; 2013; 26(6):993-1000. PubMed ID: 23543481
[TBL] [Abstract][Full Text] [Related]
11. The challenge of controlling phosphorus in chronic kidney disease.
Cannata-Andía JB; Martin KJ
Nephrol Dial Transplant; 2016 Apr; 31(4):541-7. PubMed ID: 25770169
[TBL] [Abstract][Full Text] [Related]
12. Nicotinamide and phosphate homeostasis in chronic kidney disease.
Ginsberg C; Ix JH
Curr Opin Nephrol Hypertens; 2016 Jul; 25(4):285-91. PubMed ID: 27219041
[TBL] [Abstract][Full Text] [Related]
13. Oh, My Gut! New insights on the role of the gastrointestinal tract and the gut microbiome in chronic kidney disease-mineral and bone disorder.
Mirmohammadali SN; Gallant KMH; Biruete A
Curr Opin Nephrol Hypertens; 2024 Mar; 33(2):226-230. PubMed ID: 38088374
[TBL] [Abstract][Full Text] [Related]
14. Phosphorus Regulation in Chronic Kidney Disease.
Suki WN; Moore LW
Methodist Debakey Cardiovasc J; 2016; 12(4 Suppl):6-9. PubMed ID: 28298956
[TBL] [Abstract][Full Text] [Related]
15. Role of Chronic Kidney Disease (CKD)-Mineral and Bone Disorder (MBD) in the Pathogenesis of Cardiovascular Disease in CKD.
Yamada S; Nakano T
J Atheroscler Thromb; 2023 Aug; 30(8):835-850. PubMed ID: 37258233
[TBL] [Abstract][Full Text] [Related]
16. Npt2b deletion attenuates hyperphosphatemia associated with CKD.
Schiavi SC; Tang W; Bracken C; O'Brien SP; Song W; Boulanger J; Ryan S; Phillips L; Liu S; Arbeeny C; Ledbetter S; Sabbagh Y
J Am Soc Nephrol; 2012 Oct; 23(10):1691-700. PubMed ID: 22859851
[TBL] [Abstract][Full Text] [Related]
17. Dietary Protein Intake and Bone Across Stages of Chronic Kidney Disease.
Stremke ER; Biruete A; Hill Gallant KM
Curr Osteoporos Rep; 2020 Jun; 18(3):247-253. PubMed ID: 32240477
[TBL] [Abstract][Full Text] [Related]
18. Treatment of hyperphosphatemia: the dangers of aiming for normal PTH levels.
Haffner D; Leifheit-Nestler M
Pediatr Nephrol; 2020 Mar; 35(3):485-491. PubMed ID: 31823044
[TBL] [Abstract][Full Text] [Related]
19. KDOQI US Commentary on the 2017 KDIGO Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD).
Isakova T; Nickolas TL; Denburg M; Yarlagadda S; Weiner DE; Gutiérrez OM; Bansal V; Rosas SE; Nigwekar S; Yee J; Kramer H
Am J Kidney Dis; 2017 Dec; 70(6):737-751. PubMed ID: 28941764
[TBL] [Abstract][Full Text] [Related]
20. Effects of sucroferric oxyhydroxide and sevelamer carbonate on chronic kidney disease-mineral bone disorder parameters in dialysis patients.
Ketteler M; Sprague SM; Covic AC; Rastogi A; Spinowitz B; Rakov V; Walpen S; Floege J
Nephrol Dial Transplant; 2019 Jul; 34(7):1163-1170. PubMed ID: 29846719
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
